← Eichor
Condition: Myotonic Dystrophy Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Myotonic Dystrophy

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Personalized Training for People With Rare Neuromuscular Disorders
NA · 5 location(s) · Oslo University Hospital · NCT06708468Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension
Phase N/A · 1 location(s) · Virginia Commonwealth University · NCT07700225Remote Assessments and Genetic Determinants of Myotonic Dystrophy
Phase N/A · 1 location(s) · University of Rochester · NCT07505342The United Kingdom National Registry for Myotonic Dystrophy
Phase N/A · 1 location(s) · Newcastle University · NCT04003363Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06147414Biomarker Development for Muscular Dystrophies
Phase N/A · 5 location(s) · Massachusetts General Hospital · NCT05019625Assessment of a Portable Digital Device for Quantified Analysis of Markerless Walking in Volunteers With Neuromuscular D
NA · 1 location(s) · Institut de Myologie, France · NCT07321977Pelvic Floor Muscle Training for Women with Myotonic Dystrophy
NA · 1 location(s) · Université de Sherbrooke · NCT06316778Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dys
Phase 1/Phase 2 · 20 location(s) · Dyne Therapeutics · NCT05481879The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2
Phase 3 · 7 location(s) · Lupin Ltd. · NCT06523400Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension
Phase N/A · 1 location(s) · Virginia Commonwealth University · NCT06747884An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)
Phase 2 · 3 location(s) · PepGen Inc · NCT07220603Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
Phase 3 · 21 location(s) · Dyne Therapeutics · NCT07486934Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)
Phase N/A · 17 location(s) · Virginia Commonwealth University · NCT03981575Transcriptomic Analysis to Put an End to Misdiagnosis in Patients With Rare Muscle Diseases
NA · 1 location(s) · Assistance Publique Hopitaux De Marseille · NCT06833489Assessments in Patients With Muscular Pathology and in Control Subjects : The ActiLiège Next Study
NA · 8 location(s) · Centre Hospitalier Universitaire de Liege · NCT05982119Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac Transplantation
Phase N/A · 3 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06813443A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1
Phase 2 · 8 location(s) · PepGen Inc · NCT06667453Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy
Phase 1/Phase 2 · 11 location(s) · Arrowhead Pharmaceuticals · NCT06138743Evaluation of the Role of miR-1 in the Pathogenesis and as a Biomarker in Muscular Dystrophies and Congenital Myopathies
NA · 1 location(s) · University Hospital, Clermont-Ferrand · NCT07415837Remote Assessments and Genetic Determinants of Congenital and Childhood Myotonic Dystrophy
Phase N/A · 1 location(s) · University of Rochester · NCT07630389Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
Phase N/A · 1 location(s) · University of Rochester · NCT00082108Long-Term Development of Muscular Dystrophy Outcome Assessments
Phase N/A · 1 location(s) · Virginia Commonwealth University · NCT05989620Phenotype - Genotype Correlation in a Sample of Egyptian Patients With Congenital Myopathies and Congenital Muscular Dys
Phase N/A · 1 location(s) · Ain Shams University · NCT07138963Myotonic Dystrophy Family Registry
Phase N/A · 1 location(s) · Myotonic Dystrophy Foundation · NCT02398786Study of ATX-01 in Participants With DM1
Phase 1/Phase 2 · 12 location(s) · ARTHEx Biotech S.L. · NCT06300307Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
Phase 2/Phase 3 · 14 location(s) · AMO Pharma Limited · NCT05004129DMCRN-02-001: Assessing Pediatric Endpoints in DM1
Phase N/A · 5 location(s) · Virginia Commonwealth University · NCT05224778Extracellular RNA Biomarkers of Myotonic Dystrophy
Phase N/A · 3 location(s) · Massachusetts General Hospital · NCT05020002A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Ge
Phase 1/Phase 2 · 9 location(s) · Sanofi · NCT06844214
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.